71.45
+1.20%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About WuXi XDC Cayman
Its shares trade on HKEX under the ticker 2268.HK. It has been listed since 17 November 2023. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.92bn and net income of CN¥1.72bn. At that date it held total assets of CN¥16.81bn and shareholders' equity of CN¥12.49bn.
WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Wuxi, Jiangsu. The company went IPO on 2023-11-17. WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The firm conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The firm conducts its business in domestic and foreign markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 17 Nov 2023
- Employees
- 1,113
Leadership
Pay as last reported
- Dr. Chen ZhishengNon-Executive Chairman of the Board, since 2020
- Dr. Li JincaiChief Executive Officer, Executive Director, since 2020CN¥14.8m
- Mr. Xi XiaojieChief Financial Officer, Executive Director, Company Secretary, since 2023
- Mr. Zhang JingweiChief Operating Officer, Executive Director, since 2023CN¥5.1m
- Dr. Zhu MeiyingChief Technology Officer
- Dr. Luo JianjunVice President
- Ms. Shi MingNon-Executive Director
- Dr. Zhou WeichangNon-Executive Director
- Dr. Ulf GrawunderNon-Executive Independent Director
- Mr. Zhou HaoNon-Executive Independent Director
- Mr. Kenneth HitchnerNon-Executive Independent Director
- Ms. Chris FangIR Contact Officer, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- WuXi XDC Cayman Inc employs 1,113 full-time employees in Wuxi, Jiangsu.
- The company provides CRDMO services for antibody drug conjugates and bioconjugate drugs.
- WuXi XDC Cayman Inc operates in both domestic and foreign markets for biopharmaceuticals.
Weaknesses
- The company's IPO was on 17 November 2023, a recent listing.
- WuXi XDC Cayman Inc has only two business segments.
- The company's services are limited to antibody drug conjugates and bioconjugate drugs.
Opportunities
- The growing biopharmaceuticals market offers expansion opportunities for WuXi XDC Cayman Inc.
- The demand for CRDMO services in the Life Sciences Tools & Services industry is increasing.
- WuXi XDC Cayman Inc can leverage its FFS and FTE business models for further growth.
Threats
- The Life Sciences Tools & Services industry faces intense competition from other providers.
- The biopharmaceuticals market is subject to regulatory changes and approvals.
- WuXi XDC Cayman Inc's reliance on ADCs and bioconjugate drugs may limit market diversification.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.